Exagen Inc. Common Stock (XGN) Stock Price
XGNStock
$7.72−34.41%52W
Market Cap$187.02M
P/E—
PEG Ratio—
Div yield—
Beta2.28
XGN Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)144.04%
Price vs S&P 500 (4W)-9.12%
VGM Score48.06
XGN Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.17 | -$0.11 | +32.59%(+$0.06) | |
| Q1 2026 | -$0.25 | -$0.20 | +18.68%(+$0.05) | |
| Q4 2025 | -$0.19 | -$0.27 | -37.69%(-$0.07) | |
| Q3 2025 | -$0.16 | -$0.31 | -96.83%(-$0.15) | |
| Q2 2025 | -$0.15 | -$0.18 | -18.78%(-$0.03) |
XGN Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.18
4.17
4.17
4.17
Industry Peers — Health Services(30)
| Symbol | Value Score | Growth Score | Momentum Score | P/E Ratio (Annual) | Revenue Growth TTM (YoY) | Operating Margin (TTM) | ROE (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
XGNExagen Inc. Common Stock | D | C | B | — | 20.8% | -18.6% | -121.6% | $7.72 |
| NTRANatera, Inc. Common Stock | F | A | A | — | 37.8% | -10.7% | -11.7% | $393.44 |
| DGXQuest Diagnostics Inc. | C | D | B | 26.1x | 9.9% | 14.1% | 14.5% | $235.00 |
| LHLabcorp Holdings Inc. | C | D | B | 29.4x | 6.4% | 10.4% | 11.6% | $317.95 |
| GHGuardant Health, Inc. Common Stock | F | A | B | — | 42.7% | -40.2% | -246.6% | $158.60 |
| CAICaris Life Sciences, Inc. Common Stock | F | A | B | — | 38.5% | 12.7% | 18.8% | $30.56 |
| RDNTRadNet, Inc. Common Stock | D | C | C | 1779.3x | 18.9% | 3.0% | -1.9% | $68.80 |
| GRALGRAIL, Inc. Common Stock | D | B | B | — | 23.1% | -338.4% | -15.9% | $117.81 |
| BLLNBillionToOne, Inc. Class A Common Stock | F | F | C | 621.1x | — | 10.9% | 8.9% | $98.12 |
| VCYTVeracyte, Inc. | D | B | C | 52.2x | 17.3% | 19.6% | 8.6% | $43.12 |
| CDNACareDx, Inc. | D | B | A | 18.3x | 34.4% | 23.6% | 32.8% | $64.00 |
About Exagen Inc. Common Stock
Exagen Inc is a commercial-stage diagnostics company offering ten testing solutions under the Avise brand for autoimmune rheumatic diseases (ARDs). The company's products enable community rheumatologists to accurately diagnose and monitor ARD patients while optimizing treatment decisions. Exagen addresses unmet diagnostic needs in a key therapeutic area.